Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALYPSO
2022-503126-12-00Phase 3Withdrawn
- Sponsor
- Amolyt Pharma
- Start
- Jul 2023
- Modality
- Small Molecules, Peptides
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in hypoparathyroidism comparing Eneboparatide with Placebo (2 arms). Primary endpoint: Composite response at Week 24. Planned start Jul 2023; status: withdrawn.
02
Drugs
eneboparatide
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on 2022-503126-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503126-12-00.